NEUTRALIZING ANTIBODIES TO INTERFERON-ALPHA - RELATIVE FREQUENCY IN PATIENTS TREATED WITH DIFFERENT INTERFERON PREPARATIONS

被引：200
|
作者：
ANTONELLI, G
CURRENTI, M
TURRIZIANI, O
DIANZANI, F
机构：
[1] Institute of Virology, University La Sapienza, 00185 Rome
来源：
JOURNAL OF INFECTIOUS DISEASES | 1991年 / 163卷 / 04期
关键词：
D O I：
10.1093/infdis/163.4.882
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The frequencies of antibody development so far reported in patients treated with different interferons (IFNs) are not readily comparable because of differences in treatment regimens and assay methods. Thus the frequency of neutralizing antibody development was analyzed in a large sample of sera derived from a relatively homogeneous group of patients treated with different IFN-alpha preparations. The frequency of developing neutralizing antibody to IFN varied according to the IFN given. Particularly, the seroconversion frequency was significantly higher in patients treated with recombinant IFN-alpha-2a (20.2%) than in patients treated with either recombinant IFN-alpha-2b (6.9%) or IFN-alpha-N1 (1.2%), a lymphoblastoid IFN-alpha. Furthermore, sera obtained from patients treated with either recombinant IFN neutralized both types of recombinant IFNs but failed to neutralize IFN-alpha-N1.
引用
收藏
页码：882 / 885
页数：4
相关论文
共 50 条
  • [21] INTERFERON-ALPHA ANTIBODIES IN AUTOIMMUNE-DISEASES
    PRUMMER, O
    SEYFARTH, C
    SCHERBAUM, WA
    DREES, N
    PORZSOLT, F
    JOURNAL OF INTERFERON RESEARCH, 1989, 9 : S67 - S74
  • [22] Interferon β neutralizing antibodies in multiple sclerosis:: neutralizing activity and cross-reactivity with three different preparations
    Bertolotto, A
    Malucchi, S
    Milano, E
    Castello, A
    Capobianco, M
    Mutani, R
    IMMUNOPHARMACOLOGY, 2000, 48 (02): : 95 - 100
  • [23] Interferon-alpha suppresses leptin levels: Studies in interferon-alpha treated patients with hepatitis C virus infection and murine adipocytes
    Kaser, S
    Kaser, A
    Vogel, W
    Patsch, JR
    Tilg, H
    EUROPEAN CYTOKINE NETWORK, 2002, 13 (02) : 225 - 229
  • [24] The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta
    Rice, G
    ARCHIVES OF NEUROLOGY, 2001, 58 (08) : 1297 - 1298
  • [25] Neutralizing antibodies to interferon
    Noronha, Avertano
    NEUROLOGY, 2007, 68 : S16 - S22
  • [26] Antiplatelet antibodies in patients with chronic viral hepatitis receiving interferon-alpha
    Christodoulou, Dimitrios
    Christou, Leonidas
    Zervou, Eleftheria
    Katsanos, Konstantinos
    Kitsanou, Margarita
    Tsianos, Epameinondas V.
    HEPATO-GASTROENTEROLOGY, 2007, 54 (78) : 1761 - 1765
  • [27] Pegylated interferon alpha and anti-interferon neutralizing antibodies development in chronic hepatitis C patients
    Bellomi, F.
    Milella, M.
    Gaeta, G. B.
    Angarano, G.
    Giannelli, G.
    Caporaso, N.
    Scagnolari, C.
    Muto, A.
    Dianzani, F.
    Antonelli, G.
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2007, 27 (08): : 733 - 733
  • [28] NEUTRALIZING INTERFERON-BETA ANTIBODIES IN MELANOMA PATIENTS TREATED WITH RECOMBINANT AND NATURAL INTERFERON-BETA
    FIERLBECK, G
    SCHREINER, T
    SCHABER, B
    WALSER, A
    RASSNER, G
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1994, 39 (04) : 263 - 268
  • [29] COST OF RENAL CELL CARCINOMA TREATMENT IN PATIENTS TREATED WITH INTERFERON-ALPHA
    Purmonen, T.
    Vuorinen, R.
    Kataja, V
    Pyrhonen, S.
    Kellokumpu-Lehtinen, P.
    VALUE IN HEALTH, 2009, 12 (07) : A266 - A267
  • [30] Assays for antibodies to human interferon-alpha: The need for standardization
    Schellekens, H
    Ryff, JC
    VanderMeide, PH
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1997, 17 : S5 - S8
12345